摘要
目的观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法对50例经病理确诊的晚期NSCLC患者,采用培美曲塞500 mg/m2d1+顺铂25 mg/m2d1-3天治疗,21 d为一周期。2个周期后评价疗效、毒副反应。结果患者客观有效率62%,疾病控制率89%,中位无进展生存期9.45个月,中位生存期11.35个月,1a生存率46%;患者毒副反应主要是骨髓抑制、胃肠道反应,均未达到Ⅲ～Ⅳ度。结论培美曲塞联合顺铂一线治疗晚期NSCLC疗效肯定,毒副反应轻,患者耐受性好,临床疗效肯定。
Objective To observe the efficacy and adverse effect of pemetrexed combined with cisplatin in the first-line treatment of advanced non small cell lung cancer （NSCLC）. Methods 50 patients with advanced NSCLC were treated with pemetrexed 500 mg/ m2dl plus cisplatin 25 mg/m2dl-3, intravenous drip, and dexamethasone and folic acid orally. At the same time, they were intramuscu- larly injected with vitamin B12. After 42 days （2 cycles） the efficacy and adverse effect were evaluated. Results The effective rate was 62% and the disease control rate was 89%. The median progression-free survival was 9.45 months, and the median survival time was 11.35 months. 1A survival rate was 46%. The major adverse effects were bone marrow depression and gastrointestinal reactions, none of which reached the grade III or IV. Conclusion Pemetrexed combined with cisplatin as the first-line therapy for advanced NSCLC has a positive efficacy, which shows less adverse effect and better toleration by patients.
出处
《临床肺科杂志》
2012年第12期2249-2250,共2页
Journal of Clinical Pulmonary Medicine
关键词
培美曲塞
顺铂
非小细胞肺癌
化疗
pemetrexed
cisplatin
non small cell lung cancer
chemotherapy
